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SUMMARY. Activity of Eosinophilic Esophagitis (EoE) can be measured by patient reported outcomes (symp-
toms and quality of life) and clinician-reported outcomes (endoscopic, histologic, or biochemical alterations). Over
the last years efforts have been underway to develop and validate instruments to assess EoE activity in the different
domains. Such instruments are urgently needed to standardize the language of EoE activity assessment and, in so
doing, to facilitate communication among various stakeholders. Such standardization will ultimately allow EoE
researchers to define meaningful endpoints for use in clinical trials and observational studies, to compare the
efficacy of different therapeutic modalities, and to develop algorithms in order to provide patients with the
appropriate therapy. This review provides an overview of the current status of instruments that assess EoE activity
in the different domains.
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INTRODUCTION
Why is it important to measure EoE activity?
Eosinophilic esophagitis (EoE) has first been recog-
nized as distinct disease entity in the early 1990s.1,2
An increasing incidence and cumulative prevalence
of EoE has been noted in industrialized countries
with current incidence rates of about 1 new patient
in 10,000 inhabitants per year and current preva-
lence rates of approximately 1 patient per 2000
inhabitants.3–6 The first comprehensive definition of
EoE was published in 2007.7 In the updated 2011
version, EoE was defined by a panel of international
experts as ‘a chronic, immune/antigen-mediated,
esophageal disease, characterized clinically by
symptoms related to esophageal dysfunction and his-
tologically by eosinophil-predominant inflamma-
tion’.8 Other conditions associated with esophageal
eosinophilia, such as gastroesophageal reflux disease
(GERD), Crohn’s disease, or achalasia, should be
excluded before EoE can be diagnosed.
Given the fact that EoE has been first described a
little over 20 years ago, it is not astonishing that until
recently, no validated instruments to assess different
aspects of EoE activity existed. The use of different,
either non-EoE-specific or non-validated, instru-
ments to assess EoE symptom severity may explain
why a dissociation between EoE symptom severity
and histologic activity has been documented in
some,9–11 but not other studies.12,13 In recent years,
efforts have been underway to develop and validate
instruments to assess EoE activity. Validated instru-
ments are urgently needed in order to standardize the
language of EoE activity assessment and, in so doing,
to facilitate communication among the various EoE
stakeholders, including patients, industry, physicians,
and researchers. This standardization will, in turn,
allow EoE researchers to define clinically meaningful
end-points for use in clinical trials and observa-
tional studies, to compare the efficacy of different
Address correspondence to: Dr Alain Schoepfer, MD, PD +
MER1, Division of Gastroenterology and Hepatology, Centre
Hospitalier Universitaire Vaudois/CHUV, Rue de Bugnon 44,
07/2409, 1011 Lausanne, Switzerland. Email:
alain.schoepfer@chuv.ch
Disclaimers: The authors are among the copyright holders of the
Eosinophilic Esophagitis Activity Index (EEsAI) Patient
Reported Outcomes Instrument that is copyrighted by University
of Bern, Switzerland. Please contact the corresponding author
for questions regarding the use of the EEsAI PRO instrument
for clinical trials.
Grant support: This work was supported by a grant from
TIGERS (The International Gastrointestinal Eosinophil
ResearcherS) and the Swiss National Science Foundation (Grant
No. 32003B_135665/1 to AMS and AST).
Conflict of interest: None related to this manuscript.
Published in final edited form as: Dis Esophagus. 2016 Nov;29(8):959-966. doi: 10.1111/dote.12391
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
9
5
9
8
0
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
therapeutic modalities, and to develop therapeutic
algorithms in order to provide patients with the
appropriate therapy.
EoE activity assessment: capturing the multiple facets
of the disease
EoE diagnosis is based on two pillars: symptoms and
histology. This duality needed for establishing EoE
diagnosis points to the fact that overall EoE activity
should be assessed by taking into account various
patient reported outcomes (PRO) and clinician-
reported outcome (ClinRO) measures (Fig. 1).
PRO measures in EoE include those that assess
symptom severity, quality of life, and behavioral
adaptations to living with dysphagia. Our group has
recently shown that EoE patients frequently avoid
dense foods, modify the food to ease the swallowing,
or take longer to eat a meal.14 Evaluating the extent to
which patients practice these behaviors represents an
integral part of EoE activity assessment. It is impor-
tant to point out that patients should report their
symptoms, behavioral adaptations to living with
dysphagia, and quality of life without any help from
physicians in order to avoid potential physician-
inherent biasing.15,16 ClinRO measures in EoE include
assessment of endoscopic, histologic, and laboratory
findings, as well as assessment of other aspects of
gastrointestinal physiology.
In general, the utility of PRO and ClinRO mea-
sures in overall disease activity assessment strongly
depends on the impact of the disease-inherent altera-
tions on the PRO measures and availability of suit-
able biologic measures (e.g. biomarkers) that can be
used as indicators of disease severity. We have
recently described this concept elsewhere.17 In our
opinion, both PRO and ClinRO measures contribute
in an important way to overall EoE activity. When
EoE is untreated, ongoing eosinophil-predominant
inflammation results in development of esophageal
remodeling and fibrosis. It is well documented that
these underlying changes are associated with EoE-
associated endoscopic findings, such as stricture(s)
and luminal narrowing.18–22 Esophageal strictures, in
turn, are associated with dysphagia episodes and rep-
resent the main risk factor for food bolus impactions
and a potential risk for impaction-associated esopha-
geal perforations.23,24 Given the fact that in EoE
severity of inflammation and stricture formation are
associated with symptom severity, both PRO and
ClinRO should be used to assess disease activity.17,25
Defining end-points for clinical trials
To date, no EoE-specific pharmacologic therapy has
been approved by the United States Food and Drug
Administration (US FDA) and the European Medi-
cines Agency (EMA). Nonetheless, several clinical
trials that evaluate the efficacy of medications in EoE
patients are currently ongoing. The sponsors of these
trials face numerous challenges, and, among them,
the lack of EoE-specific instruments that have been
deemed by US FDA as qualified for use as end-points
in exploratory studies. The US FDA has played an
active role in fostering collaborations among differ-
ent stakeholders in order to develop clinical outcome
assessment tools to support drug development and to
establish meaningful endpoints to be used in clinical
trials, and observational studies.15,16 These concerted
efforts should ultimately provide EoE patients with
much needed therapies.
Challenges in clinical EoE activity assessment
PRO measures can be separated into instruments that
assess symptoms, behavioral modifications, and
quality of life. Given the fact that challenges in assess-
ing EoE symptoms and developing PRO instruments
are numerous, our discussion is limited to a few
aspects that we feel merit particular attention. First,
EoE symptom presentation varies with age.1,2,26
Infants and toddlers typically present with feeding
difficulties and failure to thrive, whereas school-aged
children often present with vomiting and abdominal
pain.1,2,26 Adolescent and adult EoE patients mostly
suffer from dysphagia and food impactions.1,2,26 This
age-dependent symptom presentation should be
taken into account when developing instruments to
assess clinical EoE activity. For pediatric patients
specifically, different PRO instruments should be
developed for patients of different ages: instruments
that can be completed by older children themselves,
and instruments that should be completed by
someone other than the patient (a parent, caregiver,
or someone, who observes the patient in daily life) for
children that are too young to complete the instru-
ment on their own. Second, a distinct time period
Fig. 1 Capturing all facets of the disease for activity
assessment.
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has to be defined for patients to recall their symp-
toms. For clinical trials, regulatory authorities favor
the use of a daily electronic diary. However, daily
diaries may not be practical for use in settings other
than pharmaceutical company-sponsored clinical
trials. Third, measuring the severity of the key EoE
symptom, dysphagia, strongly depends on the consis-
tency of the ingested food. In practical terms, when
asked by a physician, ‘Do you have dysphagia?’, the
patient consuming a diet consisting of mostly soft
foods, such as yoghurt and soup, is likely to answer
‘No’, even in the presence of relatively severe EoE-
specific biologic alterations. If such a patient would
then be encouraged to eat a more dense food item,
such as piece of meat or fresh bread, this patient
would be much more likely to report dysphagia.
Thus, dysphagia should be assessed in the context of
consuming foods of various consistencies. Similarly,
behavioral modifications to living with dysphagia,
such as avoidance of certain foods, modification of
foods to ease the swallowing, and a relatively long
time required to eat certain food items, should also be
taken into account and assessed in the context of
eating foods of various consistencies (Fig. 2).
INSTRUMENTS THAT ASSESS PRO
MEASURES IN EoE
The purpose of this section is to provide an overview
of the different EoE-specific PRO instruments pub-
lished to date (Table 1). Instruments are presented in
order of publication from latest to oldest.
Instruments for assessment of clinical activity in adult
EoE patients
EoE Activity Index (EEsAI) PRO instrument
In 2014, the international EEsAI study group pub-
lished a study on development and validation of the
EEsAI PRO instrument.14 In the process of the devel-
opment and validation of the instrument, the group
followed recommendations of the US FDA.15 Patient
(n = 186) input on EoE symptoms was sought using a
mixed methods approach, consisting of surveys, cog-
nitive individual patient interviews, and focus groups
that were guided by a psychologist. The newly created
instrument (in paper form) containing items assessing
various EoE symptoms was completed by 153 adult
EoE patients. The patient global assessment of EoE
symptom severity recalled over three distinct periods
(24 hours, 7 days, and 30 days) was also collected.
Multivariable linear regression analysis and analysis
of variance with patient global assessment as an
outcome and items of the instrument as predictors
was used to obtain an equation for constructing a
PRO score by quantifying the extent to which
included items explained the variability in patient
global assessment. Items addressing various charac-
teristics of dysphagia, behavioral adaptations to
living with dysphagia, and pain while swallowing
were included in a preliminary version of the score.
This score for a 24-hour and 7-day recall period was
validated in a second independent group of 120
patients recruited in Switzerland (German and
French) and the United States (English). The final
score ranges from 0 to 100 points and includes
seven items that assess frequency and duration of
dysphagia episodes, severity of dysphagia caused by
eating foods of eight different consistencies, and
behavioral adaptations to living with dysphagia also
assessed in the context of eating foods of eight differ-
ent consistencies. Practicality and content validity
were assessed by conducting cognitive debriefings.
Patients took a median of 8 minutes (interquartile
range 7–9, range 4–10 minutes) to complete the
EEsAI PRO instrument and judged the instrument to
be easy to complete.14 Furthermore, patients consid-
ered the EEsAI PRO instrument as adequate in
assessing relevant EoE-related complaints (content
validity).14 The EEsAI PRO instrument, which is
copyrighted by the University of Bern, Switzerland, is
currently being used in different clinical trials.
Dysphagia Symptom Questionnaire (DSQ)
In 2013, Dellon et al. published the study on devel-
opment of the DSQ, a three-item electronic diary.27
The diary was developed in collaboration with the
Meritage Pharma, Inc. (the copyright holder). In the
first phase, 10 adolescent and 10 adult EoE patients
were enrolled into face-to-face concept elicitation and
cognitive interview sessions in order to create the
diary. Adolescent and adult patients with symptoms
of dysphagia were enrolled. At the time of the study,
esophageal biopsies of these patients had at least
15 eosinophils per high-power field. Solid-food-
avoidance days, dysphagia days, and actions taken to
get dysphagia relief were recorded. The consistency of
solid food was not specified. The scoring algorithm
was expert-based and was constructed by giving each
item response a discrete value, which were then
Fig. 2 Factors influencing patient’s perception of dysphagia.
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totaled for each week. This total was divided by the
number of days the DSQ was completed. The DSQ
score ranges from 0 to 5. A total 18 adults and 17
adolescents completed the field trial. The DSQ score
strongly correlated with the number of dysphagia
days (R = 0.96, P < 0.001) and showed to be content
valid. The DSQ is currently being used in a clinical
trial (E Dellon, pers. comm. 2015).
Straumann Dysphagia Index (SDI) instrument
SDI is a non-validated PRO instrument that was first
evaluated in a natural history study by Straumann
et al. (published in 2003) and subsequently used, in a
modified form, in a randomized, placebo-controlled
trial by Straumann et al. (published in 2010) evaluat-
ing the efficacy of swallowed topical budesonide in 36
adult EoE patients.12,35 The instrument was developed
using physician input, and the scoring algorithm for
this instrument is expert-based. The SDI assesses the
following EoE symptoms: (i) frequency of dysphagia
events and (ii) intensity of dysphagia events. The
SDI score ranges from 0 to 9 points. Treatment with
swallowed topical budesonide significantly reduced
esophageal peak eosinophil counts, and the SDI was
Table 1 Overview of the instruments that assess symptoms and quality of life in adult and pediatric EoE patients
Name of the
instrument Characteristics Languages References
Clinical activity
in adult EoE
patients
EoE Activity
Index (EEsAI)
PRO
instrument
• Developed using patient input
• Score evaluated in 153 patients and validated in 120 patients –
based on patient global assessment
• Recall period: 7 days and 24 hours
• Completion time: 8 minutes
• Content valid
English
German
French
Schoepfer
et al.14
Dysphagia
Symptom
Questionnaire
(DSQ)
• Developed using patient input
• Field-tested in 35 adolescent and adult patients
• Expert-based scoring algorithm
• Recall period: 24 hours (daily electronic diary)
• Content valid
English Dellon et al.27
Straumann
Dysphagia
Index (SDI)
• Developed using physician input
• Expert-based scoring algorithm
• Recall period: 7 days
• Evaluated in a RPCT in 36 patients
English
German
Straumann
et al.12
Mayo Dysphagia
Questionnaire
(MDQ)
• Developed and validated to assess dysphagia in adults with
different esophageal diseases (physician input was used for item
generation)
• Recall period: 14 days and 30 days
• Completion time: 10 minutes
• Content valid
• Evaluated in a RPCT in 42 adults with EoE
English Grudell
et al.28 and
McElhiney
et al.29
Clinical activity
in pediatric
EoE patients
Clinical
symptom score
(CSS)
• Developed using physician input
• Evaluated in a RPCT in 71 pediatric patients aged 2–18 years
• Expert-based scoring algorithm
• Recall period: 14 days
English Gupta et al.11
Pediatric EoE
symptom score
(PEESS,
Version 2.0)
• Developed using patient and parent input (children 2–18 years
of age)
• Only qualitative methods have been published
• expert-based scoring algorithm
• Recall period: 30 days
English Franciosi
et al.30
Symptom
scoring tool
(SST)
• Developed using physician input
• Field tested in 35 EoE patients, 27 GERD patients and 38
controls
• Completed by children and parents
• Expert-based scoring algorithm
• Evaluated in a RPCT in 24 pediatric patients
English Aceves et al.31
Pediatric EoE
symptom
instruments by
Flood et al.
• Questionnaires for parents of EoE patients 2–7 years of age and
patients 8–17 years of age
• Recall period: 24 hours
• Expert-based scoring algorithm
• Content valid
• Score not validated
English Flood et al.32
Quality of life Adult EoE
quality of life
instrument
(EoO-QOL-A)
• Developed using patient input
• Validated in adult EoE patients 18–70 years of age
• Good internal consistency and test–retest reliability
• Recall period: 7 days
English
Spanish
Taft et al.33
PedsQL module • Developed using patient input
• Validated in pediatric EoE patients 5–18 years of age
• Good feasibility, reliability, test–retest reliability
• Recall period: 30 days is described in the study, but 7-day recall
is also available
English Franciosi
et al.34
Instruments are listed according to the year of publication, with the most recent listed first. RPCT, randomized, placebo-controlled trial.
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responsive.35 A clinical response was defined as a ≥
3-point decrease from the SDI score baseline value.
The SDI does not assess dysphagia caused by eating
foods of different consistencies and does not take
into account behavioral adaptations to living with
dysphagia.
Mayo Dysphagia Questionnaire (MDQ)
The MDQ has been developed and validated by
Grudell et al.28 The MDQ consists of a total of
28 items. Of these, 17 items assess frequency and
severity of dysphagia, 3 items assess the presence of
concomitant allergies, 3 items assess the use of acid-
suppressive medication, 2 items evaluate the presence
of esophageal surgery, 1 item assesses the presence of
GERD, 1 item evaluates esophageal dilations, and 1
item evaluates the overall duration of trouble swal-
lowing. Assessment of dysphagia severity is carried
out in the context of consuming foods of different
consistencies. In addition, patients are also ques-
tioned about food modification and time to eat a
regular meal. The MDQ aims to evaluate dysphagia
in adult patients with different esophageal disorders
and has not specifically been developed and validated
for adult EoE patients. The reliability and validity of
the MDQ, 30-day version (MDQ-30), has been docu-
mented in a large population of patients suffering
from dysphagia.29 The MDQ-30 takes an average of
10 minutes to complete. The MDQ-30 is copyrighted
by Mayo Clinics. The MDQ 2-week version, has been
used in a double-blind, randomized, placebo-
controlled trial evaluating efficacy of fluticasone in 42
adults with a new EoE diagnosis.9 The treatment with
aerosolized, swallowed fluticasone led to histologic
but not symptom response, with response defined
as either complete lack of trouble swallowing or
decrease in frequency or severity of this symptom.
Instruments for assessment of clinical activity in
pediatric EoE patients
Clinical symptom score (CSS)
Gupta et al. evaluated the CSS when conducting a
randomized, placebo-controlled trial on efficacy of
12-week oral budesonide suspension treatment in a
group of 71 pediatric EoE patients between the ages 2
and 18 years old.11 The CSS is a newly developed,
non-validated symptom score adapted from a previ-
ously published symptom scoring tool (SST).36 It is
based on the physician assessment of the frequency
and disruptiveness of multiple symptoms including
heartburn, abdominal pain, nocturnal awakening
with various symptoms, nausea, regurgitation or vom-
iting, anorexia or early satiety, dysphagia,
odynophagia or food impaction, and the use and dis-
ruptiveness of coping behaviors, as determined by
questioning the patient and/or caregiver. The CSS
does not assess symptoms in the context of eating
foods of different consistencies. Each symptom cat-
egory is scored by the experts on a scale from 0 to 3
points. In order to be scored, the symptom must have
been present in the period of the last 14 days before the
assessment. The total CSS ranges from 0 to 18 points.
A clinical response was defined as a ≥ 50% reduction in
the CSS. Given the fact that a large percentage of
placebo-treated patients demonstrated symptom
improvement, there was no significant difference in
clinical response between oral budesonide suspension
treatment groups and the placebo group.11
Pediatric EoE symptom score (PEESS)
In 2011, Franciosi et al. published the study on the
qualitative methodology used for the development of
the PEESS, version 2.0.30 Authors followed the FDA
guidelines for PRO development.15 The authors con-
ducted of total of 75 interviews with children (ages
8–12 and 13–18 years) and parents (caregivers) (ages
2–4, 5–7, 8–12, and 13–18 years) to construct the
PRO instrument. Domains assessing frequency and
severity of various symptoms were developed, and
open-ended questions were used to generate specific
items during the individual focus interviews. This was
followed by cognitive interviews for face and content
validation. Later on, the instrument construct,
instructions, timeframe, scoring, and specific items
were reviewed with a separate EoE patient group and
their parents during the cognitive interviews. Each
item was scored on a scale from 0 to 4. The symptoms
were recalled over a period of 30 days. Results of the
field-testing process (evaluation phase) and the vali-
dation phase have not yet been published.
Symptom scoring tool
Aceves et al. developed and prospectively evaluated a
PRO instrument, the so-called SST, to discriminate
pediatric patients with EoE from those with GERD
or other atopic and non-atopic conditions.31 This
symptom score is a modified version of the score
developed for children with acid-peptic disease.37 The
instrument was tested in 35 EoE patients (not receiv-
ing anti-eosinophil therapies), 27 GERD patients
(not undergoing acid suppression), and 38 control
patients. The overall symptom score was higher in
patients with EoE and GERD when compared with
control patients. The SST assesses the frequency
and severity of the following groups of symptoms:
heartburn/regurgitation, abdominal pain, nausea/
vomiting, anorexia/early satiety, dysphagia,
symptom-induced nocturnal wakening, and gastroin-
testinal bleeding. For each of the seven groups of
symptoms, a maximum of 2 points can be given for a
most severe for of a symptom. The score ranges from
0 to 14 points. The SST has been developed using
physician input and is completed by parents and
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children. The SST does not assess dysphagia caused
by eating foods of different consistencies. Authors
showed that only dysphagia and anorexia/early
satiety could discriminate EoE patients from GERD
patients. Dysphagia and anorexia/early satiety also
correlated with the severity of EoE-associated histo-
logic and endoscopic findings (P < 0.05).31 In a ran-
domized, placebo-controlled trial evaluating the
efficacy of oral viscous budesonide treatment in pedi-
atric patients with histologically and clinically active
EoE, the authors found that the SST score decreased
in the treatment group when compared with placebo
(P = 0.031) over a 12-week treatment period.38
Pediatric EoE symptom instrument by Flood et al.
In 2008, Flood et al. were the first to publish a study on
the development of pediatric EoE symptom instru-
ments.32 The authors developed the instruments based
on a review of the literature and clinical expert consul-
tation. Specifically, the instrument for the parent/
caregiver consists of five items, including those on
intensity of pain in the stomach and in the chest,
frequency of vomiting, as well as trouble swallowing
and pain when drinking and eating. The instrument
for children and teenagers consists of six items; in
addition to items assessing all the symptoms already
described for the parent/caregiver instrument, an
item on being bothered by a lump in the throat was
included. Each item was scored on a scale from 1 to 5.
They then interviewed (one-to-one interviews) parents
of EoE patients aged 2–7 years (n = 12) and EoE
patients aged 8–17 years (n = 16) about EoE-related
symptoms and their impact on everyday life, using
open-ended questions, to confirm the appropriateness
of the item content of the instruments. Participants
then completed the appropriate symptom instruments
and were asked to provide feedback on the relevance,
comprehensiveness, and clarity of each item. The
symptom recall period for the caregiver and the
patient instruments was 24 hours. Overall, partici-
pants thought that the instruments were clear,
relevant, and appropriate for symptom assessment.
The instruments did neither assess symptoms in the
context of consuming foods of different consistencies
nor evaluated behavioral adaptations to living with
EoE-related symptoms. The scoring algorithm was
based on expert input. Data on the construct validity,
reliability, and responsiveness of the measures have
not been published to date.
Instruments for assessment of quality of life in adult
and pediatric EoE patients
Adult EoE quality of life (EoO-QOL-A) instrument
In 2011, Taft et al. published a study on development
and validation of the first quality of life instrument for
adult EoE patients, the adult EoO-QOL-A instru-
ment.33 A total of 201 patients, between 18 and 70
years of age, participated in the study. Using qualita-
tive methods, the authors studied the disease-specific
concerns and their impact on quality of life and iden-
tified items for the five following subscales to be
included into the EoO-QOL-A instrument: eating/diet
impact, social impact, emotional impact, disease
anxiety, and choking anxiety. The EoO-QOL-A
instrument consists of 37 items. Patients not currently
being treated by elimination diets are completing 32
items. A 7-day recall period was chosen to assess
impact of EoE on quality of life. The EoO-QOL-A
instrument demonstrated excellent internal consis-
tency, split-half and test–retest reliability. The
instrument is copyrighted by the Northwestern Uni-
versity (Chicago, IL, USA).
Pediatric quality of life (PedsQL) module
In 2013, Franciosi et al. published a study on a
quality of life instrument for pediatric EoE patients,
the so-called PedsQL EoE Module.34 The PedsQL
EoE Module was completed by 196 pediatric EoE
patients and 262 parents. The 33-item PedsQL EoE
Module encompasses seven scales, including two
symptoms scales (assessing chest/throat/stomach
pain, nausea/vomiting, and trouble swallowing),
treatment scale, worry scale, communication scale,
food and eating scale, and food feelings scale. The
recall period for the PedsQL EoE Module utilized in
the published study was 30 days. The PedsQL EoE
Module scales evidenced excellent feasibility, excel-
lent group comparison reliability across total scale
scores, good reliability for the seven individual scales,
and excellent test–retest reliability. PedsQL EoE
Module scores were worse among patients with active
histologic disease (defined as ≥ 5 eosinophils per high-
power field) when compared with those in histologic
remission and those treated with dietary restrictions
compared with those with no restrictions.
ASSESSING BIOLOGIC MEASURES IN EoE
Endoscopic activity
EoE Endoscopic Reference Score (EREFS)
grading system
Hirano et al. have recently published a study on a
classification and grading system for endoscopic
assessment of esophageal EoE features.39 This
system, also known as EREFS system, evaluates the
severity of the following endoscopic features: exu-
dates, rings, edema, furrows, and strictures. Endo-
scopic videos from 25 EoE patients and control
patients were reviewed by 21 gastroenterologists.
Interobserver agreement was assessed by estimating
multi-rater κ and the proportion of pairwise agree-
ment. The instrument standardizes the long-needed
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common nomenclature and severity grading for
the assessment of endoscopic disease activity. The
EREFS grading system showed good interobserver
agreement among practicing and academic gastroen-
terologists. The EREFS grading system is not an
endoscopic score in the strict sense of the wording.
Definitions regarding endoscopic remission, mild,
moderate, or severe endoscopic activity have not yet
been established.
Histologic activity
As of yet, no validated histology score for pediatric
and adult EoE patients exists. Assessing histologic
activity mainly relies on the peak eosinophil count
per high-power field. Additional histologic findings,
such as basal layer hyperplasia, papillary elongation,
eosinophil degranulation, or subepithelial fibrosis,
have also been reported as important histologic
outcome parameters. In 2007, Dellon et al. have
shown that peak eosinophil counts reported in
various studies may not be necessarily comparable as
different microscope types with different hight power
field sizes are used in different studies.40 Reporting the
observed peak eosinophil counts standardized to
mm2 could standardize reporting of peak eosinophils
counts in different studies. Similar to the reporting
of endoscopic severity, no established definitions of
histologic remission, as well as mild, moderate, and
severe histologic activity currently exists.
Esophageal string test and Cytosponge
In order to avoid repetitive endoscopies in EoE
patients, several groups have evaluated minimally
invasive biologic measures, such as the esophageal
string test and the Cytosponge, in order to assess the
degree of histologic inflammation.
Furuta et al. have recently published a study on
the esophageal string test, a minimally invasive tool
to assess mucosal inflammation.41 The authors dem-
onstrated that the level of luminal eosinophil-derived
proteins extracted from the esophageal string corre-
lated with the esophageal peak eosinophil counts. As
such, this test can be considered as a good measure of
mucosal inflammation in children with EoE. The
esophageal string test will likely be useful in pediatric
EoE patients needing repeated assessment of mucosal
inflammation to spare these children the burden of
repeated endoscopy under general anesthesia.
Katzka et al. compared the accuracy, safety, and
tolerability of esophageal sample collection via
Cytosponge, an ingestible gelatin capsule containing
compressed mesh attached to a string, with those of
esophageal biopsies.42 Esophageal tissue samples
were collected from 20 EoE patients using both
Cytosponge and esophageal biopsy sampling during
endoscopy. Number of eosinophils per high-power
field and levels of eosinophil-derived neurotoxin were
determined; hematoxylin and eosin staining was per-
formed. All 20 samples collected by Cytosponge were
adequate for analysis. By using a cut-off value of 15
eosinophils per high-power field, analysis of samples
collected by Cytosponge identified 11 of the 13 indi-
viduals with active EoE (83%); additional features,
such as abscesses were also identified. Numbers
of eosinophils in samples collected by Cytosponge
correlated with those in esophageal biopsies (r = 0.50,
P = 0.025). Analysis of tissues collected by
Cytosponge identified four of the seven patients
without active EoE (57% specificity), as well as three
cases of active EoE not identified by analysis biopsy
samples. Including information on the level of
eosinophil-derived neurotoxin did not increase the
diagnostic accuracy. All patients preferred to swallow
Cytosponge when compared with undergoing endos-
copy. The authors concluded that the Cytosponge is a
safe and well-tolerated method for collecting near
mucosal specimens.
Measuring esophageal compliance and diameter using
endolumenal functional lumen imaging probe
Uncontrolled eosinophil-predominant esophageal
inflammation that persists over time leads to remod-
eling with formation of strictures.20–24 These struc-
tural esophageal abnormalities may be detected by
the means of endolumenal functional lumen imaging
probe that helps physicians to monitor esophageal
wall distensibility both to assist in diagnosis of
EoE and to track the progress of patients on various
treatments.43
OUTLOOK
Described a little over 20 years ago, EoE is still a
‘young’ disease. Nevertheless, considerable progress
has been achieved in this relatively short time interval
in regards to our understanding of EoE’s natural
history, as well as its endoscopic, histologic, and
molecular characterization. The common nomencla-
ture for assessing symptoms, quality of life, endo-
scopic, and histologic activity is about to be
standardized. Developing PRO measures in accor-
dance with US FDA guidelines and having these
newly developed instruments undergo qualification
review by the US FDA remains an important target.
We remain hopeful that some of the reviewed instru-
ments will qualify as end-points to be used in clinical
trials, and observational studies. This will help all the
EoE stakeholders to bring much needed therapies to
EoE patients.
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